Hormonal, Metabolic, and Signaling Interactions in PAH
Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Arterial Hypertension
- Heritable Pulmonary Arterial Hypertension
- Scleroderma Associated Pulmonary Arterial Hypertension
- Appetite Suppressant Associate PAH
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Vanderbilt University Medical Center
- Enrolment target
- 1,899
- Started
- September 2012
- Main results due
- July 2032
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Up to 90 years.
- Open to any sex.
- Healthy volunteers can take part.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: Project 1 Inclusion: 1. Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons 2. Age 0-90, age 12-90 for skin biopsy Exclusion: 1. Other diagnosis 2. Age greater than 90, age less than 12 or greater than 90 for skin biopsy Project 2 Inclusion: 1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons 2. 0-90 3. Subjects with reasonably easy access to clinic for blood collection and other testing 4. Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing Exclusion: 1. Other diagnosis 2. 0-90 3. Subjects with difficulty reaching clinic for blood collection and other testing 4. Subjects unable to tolerate fasting state Project 3 Inclusion: 1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons 2. 7-90 Exclusion: 1. Other diagnosis 2. Age less than 7 or greater than 90 \- Exclusion Criteria: \-
What this study is about
In the sponsor’s own words, from the registry.
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Study sites(1)
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT01884051. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me